BioSpace News Archive

Biotech Bay

Corsair Pharma, Inc. to Host Key Opinion Leader Meeting on Pulmonary Arterial Hypertension

Corsair Pharma, Inc. today announced it will host a Key Opinion Leader (KOL) webinar to discuss the current treatment landscape for Pulmonary Arterial Hypertension (PAH) on Thursday, July 8 th , at 10:30 a.m. ET.

June 24, 2021
·
4 min read
Genetown

Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day

Albireo Pharma, Inc. today announced that Ron Cooper, President and Chief Executive Officer, will present as part of a fireside chat at Piper Sandler’s Virtual EASL Takeaway Day on Monday, June 28, at 10:00 a.m. EDT.

June 24, 2021
·
1 min read
Drug Development

Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer’s Association International Conference

Longeveron Inc. announced today that an abstract summarizing the results of its Phase 1 trial of Lomecel-B infusion for patients with mild Alzheimer’s disease has been accepted for a Developing Topics poster presentation at the 2021 Annual Alzheimer’s Association International Conference.

June 24, 2021
·
4 min read
Genetown

Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class

Blood Test Predicts TNFi Response in Patients Both Naïve to and Experienced with Therapy Providers Can Access Patient-Specific Data for Optimized Therapy Selection.

June 24, 2021
·
4 min read
Deals

AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma

AbbVie (NYSE: ABBV) and Teneobio, Inc. announced today that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM).

June 24, 2021
·
5 min read
Genetown

Lyndra Therapeutics Completes $60.5 Million Series C Financing

Lyndra Therapeutics today announced the closing of its $60.5 million Series C financing.

June 24, 2021
·
4 min read
Pharm Country

Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone

PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit of EMFLAZA® (deflazacort) over prednisone for the treatment of Duchenne muscular dystrophy (DMD).

June 24, 2021
·
8 min read
FDA

Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer

Pieris Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to cinrebafusp alfa (PRS-343), a 4-1BB/HER2 bispecific, for the treatment of HER2-high and HER2-low expressing gastric cancers.

June 24, 2021
·
5 min read
Drug Development

Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration

Alpine Immune Sciences, Inc. announced today that the first patient has been dosed in Synergy, a Phase 2 study of ALPN-101 in patients with Systemic Lupus Erythematosus (SLE).

June 24, 2021
·
5 min read
Drug Development

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

– Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose – – At least 12 patients to be enrolled in each of two Phase 1b expansion cohorts: a 200 mg dose cohort and a 600 mg dose cohort – – Each cohort to be genetically enriched with NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients.

June 24, 2021
·
7 min read